Archive for October 15th, 2009

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs (PCNSD) Advisory Committee voted 12 to 1 that clinical data on Fampridine-SR 10 mg twice daily demonstrated substantial evidence of effectiveness as a treatment to improve walking in people with multiple sclerosis (MS) and voted 10 to 2 (1 abstention) that it is clinically meaningful and can be safe for use.

While gripping, lifting or manipulating an object such as drinking from a cup or placing a book on a shelf is usually easy for most, it can be challenging for those with neurological diseases such as multiple sclerosis or Parkinson’s, or for people who had a stroke. For them, the tight gripping can cause fatigue, making everyday tasks difficult.

On Saturday, October 17, leading MS researchers from around the country will meet at the Hyatt Regency, Boston to evaluate the feasibility of conducting what would be the largest clinical study ever undertaken to explore the role that Vitamin D may play in Multiple Sclerosis. The meeting will be led by Dr.